Acetylcholinesterase Biomarker has Potential to Assist in Diagnosis of Alzheimer's Disease.Business Editors & Health/Medical Writers STOCKHOLM, Sweden--(BW HealthWire)--April 10, 2000 Axonyx Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : AXYX) disclosed findings indicating that a specific species of acetylcholinesterase acetylcholinesterase /ac·e·tyl·cho·lin·es·ter·ase/ (AChE) (-ko?li-nes´ter-as) an enzyme present in the central nervous system, particularly in nervous tissue, muscle, and red cells, that catalyzes the hydrolysis of acetylcholine to is a useful biomarker in the diagnosis of Alzheimer's Disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . The findings were presented Saturday, April 8, 2000 at the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy in Stockholm, Sweden. David Small, Ph.D., Head, Laboratory of Molecular Neurobiology Neurobiology Study of the development and function of the nervous system, with emphasis on how nerve cells generate and control behavior. The major goal of neurobiology is to explain at the molecular level how nerve cells differentiate and develop their at the University of Melbourne
In 2006, Times Higher Education Supplement ranked the University of Melbourne 22nd in the world. Because of the drop in ranking, University of Melbourne is currently behind four Asian universities - Beijing University, , Australia, presented preclinical data demonstrating that a form of acetylcholinesterase (AChEAD) is specifically elevated in the frontal cortex of the brain and in the lumbar cerebrospinal fluid of Alzheimer's Disease patients. In October 1999, Axonyx and the University of Melbourne entered into a Joint Development Agreement to study this potentially clinically effective diagnostic. Axonyx has an exclusive world-wide right to license any useful candidates that emerge from this program. "The search for causative agents of Alzheimer's Disease as well as new therapies is a priority at most major pharmaceutical companies," commented Marvin S. Hausman, M.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Axonyx. "The discovery of new clinical biological markers in this devastating dev·as·tate tr.v. dev·as·tat·ed, dev·as·tat·ing, dev·as·tates 1. To lay waste; destroy. 2. To overwhelm; confound; stun: was devastated by the rude remark. condition is a critical development to assist scientists in the clinical evaluation of new drug candidates." Axonyx Inc. is a biotechnology company engaged in the discovery, acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer's Disease and other memory disorders. This press release may contain forward-looking statements or predictions. These statements represent our judgment as of this date and are subject to risks and uncertainties that could materially affect the Company. Axonyx undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion